How an Infectious Disease Doctor Is Finding Ways to Decrease COVID's Impact

For Atlanta, the coronavirus pandemic has been a tale of a divided city. While in the public light it followed suit as part of one of the last states to impose stay-at-home orders and one of the first in the nation to begin lifting them. Yet, behind the scenes at one of city's most elite universities, Amy Sherman, a 32-year-old infectious disease fellow has been hard at work. She's part of a team at one of 47 sites nationwide conducting a National Institutes of Health (NIH) study on Remdesivir—an IV-administered, antiviral medication which is a potential treatment for adults hospitalized with COVID-19.